russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2023-5563BTUXABrussjcardiol-5563Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWЛабораторные маркеры остеосаркопенического ожиренияLaboratory markers of osteosarcopenic obesityhttps://orcid.org/0000-0001-5937-4128ГриценкоО. В.GritsenkoO. V.

Гриценко Олеся Валерьевна — к.м.н., м.н.с. лаборатории исследований гомеостаза отдела экспериментальной медицины; врач кардиолог общебольничного отделения

Кемерово; Барнаул

Kemerovo; Barnaul

qritzenko.olesia@mail.ruhttps://orcid.org/0000-0002-7780-829XГруздеваО. В.GruzdevaO. V.

Груздева Ольга Викторовна — д.м.н., профессор РАН, зав. лабораторией исследований гомеостаза отдела экспериментальной медицины

Кемерово

Kemerovo

o_gruzdeva@mail.ruhttps://orcid.org/0000-0002-2810-6531ЧумаковаГ. А.ChumakovaG. A.

Чумакова Галина Александровна — д.м.н., профессор, профессор кафедры терапии и общей врачебной практики

Барнаул

Barnaul

g.a.chumakova@mail.ruhttps://orcid.org/0000-0002-4642-3610БарбарашО. Л.BarbarashO. L.

Барбараш Ольга Леонидовна — д.м.н., академик РАН, директор

Кемерово

Kemerovo

qritzenko.olesia@mail.ruФГБНУ НИИ Комплексных проблем сердечно-сосудистых заболеваний; КГБУЗ «Алтайский краевой кардиологический диспансер»РоссияResearch Institute for Complex Issues of Cardiovascular Diseases; Altai Regional Cardiology DispensaryRussian FederationФГБНУ НИИ Комплексных проблем сердечно-сосудистых заболеванийРоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian FederationФГБОУ ВО Алтайский государственный медицинский университет Минздрава РоссииРоссияAltai State Medical UniversityRussian Federation202320122023281255635563Copyright © Гриценко О.В., Груздева О.В., Чумакова Г.А., Барбараш О.Л., 20232023Гриценко О.В., Груздева О.В., Чумакова Г.А., Барбараш О.Л.Gritsenko O.V., Gruzdeva O.V., Chumakova G.A., Barbarash O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5563

Синдром остеосаркопенического ожирения подразумевает одновременное ухудшение состояния костей, мышц и избыточного отложения жира, что приводит к системной метаболической дисрегуляции. В настоящее время актуальность проблемы остеосаркопенического ожирения возрастает в связи с глобальным демографическим старением населения, высокой частотой развития ожирения, сахарного диабета 2 типа, гериатрических синдромов — саркопении и старческой астении в развитых странах современного мира. В связи с этим актуальным является поиск новых методов диагностики данного состояния, включая лабораторные маркеры. В обзоре рассмотрены современные биомаркеры остеосаркопенического ожирения.

Osteosarcopenic obesity syndrome involves the simultaneous deterioration of bone, muscle, and excess fat accumulation, resulting in systemic metabolic dysregulation. Currently, the relevance of this problem is increasing due to the global population aging, the high incidence of obesity, type 2 diabetes, sarcopenia and frailty in developed countries of the modern world. In this regard, novel diagnosis methods for this condition, including laboratory markers, should be developed. The review examines modern biomarkers of osteosarcopenic obesity.

остеосаркопеническое ожирениебиомаркерыбиохимические маркерыosteosarcopenic obesitybiomarkersbiochemical markersИсследование выполнено за счет гранта Российского научного фонда № 22-15-00305 "Патофизиологические особенности формирования остеосаркопенического ожирения при мультифокальном атеросклерозе как маркера биологического старения"The study was supported by the Russian Science Foundation grant № 22-15-00305 "Pathophysiological features of osteosarcopenic obesity development in multifocal atherosclerosis as a marker of biological aging".ReferencesТополянская С.В. Саркопения, ожирение, остеопороз и старость. Сеченовский вестник. 2020;11(4):23-35. doi:10.47093/2218-7332.2020.11.4.23-35.Topolyanskaya SV. Saecopenia, obesity, osteoporosis and old. Sechenov Medical Journal. 2020;11(4):23-35. (In Russ.) doi:10.47093/2218-7332.2020.11.4.23-35.Martín-González C, Pérez-Hernández O, García-Rodríguez A, et al. Serum Myostatin among Excessive Drinkers. Int J Mol Sci. 2023;24(3):2981. doi:10.3390/ijms24032981.Martín-González C, Pérez-Hernández O, García-Rodríguez A, et al. Serum Myostatin among Excessive Drinkers. Int J Mol Sci. 2023;24(3):2981. doi:10.3390/ijms24032981.Kelly OJ, Gilman JC, Boschiero D, Ilich JZ. Osteosarcopenic obesity: current knowledge, revised identification criteria and treatment principles. Nutrients. 2019;11(4):747. doi:10.3390/nu11040747.Kelly OJ, Gilman JC, Boschiero D, Ilich JZ. Osteosarcopenic obesity: current knowledge, revised identification criteria and treatment principles. Nutrients. 2019;11(4):747. doi:10.3390/nu11040747.Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169.Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169.Clark RV, Walker AC, Miller RR, et al. Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. J Appl Physiol. 2018;124:1-9.Clark RV, Walker AC, Miller RR, et al. Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. J Appl Physiol. 2018;124:1-9.Evans WJ, Hellerstein M, Orwoll E, et al. D 3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2019;10:14-21. doi:10.1002/jcsm.12390.Evans WJ, Hellerstein M, Orwoll E, et al. D 3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2019;10:14-21. doi:10.1002/jcsm.12390.Buehring B, Siglinsky E, Krueger D, et al. Comparison of muscle/lean mass measurement methods: correlation with functional and biochemical testing. Osteoporos Int. 2018;29:675-83. doi:10.1007/s00198-017-4315-6.Buehring B, Siglinsky E, Krueger D, et al. Comparison of muscle/lean mass measurement methods: correlation with functional and biochemical testing. Osteoporos Int. 2018;29:675-83. doi:10.1007/s00198-017-4315-6.Shankaran M, Czerwieniec G, Fessler C, et al. Dilution of oral D3-Creatine to measure creatine pool size and estimate skeletal muscle mass: development of a correction algorithm. J Cachexia Sarcopenia Muscle. 2018;9:540-6. doi:10.1002/jcsm.12278.Shankaran M, Czerwieniec G, Fessler C, et al. Dilution of oral D3-Creatine to measure creatine pool size and estimate skeletal muscle mass: development of a correction algorithm. J Cachexia Sarcopenia Muscle. 2018;9:540-6. doi:10.1002/jcsm.12278.Zanker J, Patel S, Blackwell T, et al. Walking speed and muscle mass estimated by the D3-creatine dilution method are important components of sarcopenia associated with incident mobility disability in older men: a classification and regression tree analysis. J Am Med Dir Assoc. 2020;21:1997-2002. doi:10.1016/j.jamda.2020.03.017.Zanker J, Patel S, Blackwell T, et al. Walking speed and muscle mass estimated by the D3-creatine dilution method are important components of sarcopenia associated with incident mobility disability in older men: a classification and regression tree analysis. J Am Med Dir Assoc. 2020;21:1997-2002. doi:10.1016/j.jamda.2020.03.017.Cawthon PM, Blackwell T, Cummings SR, et al. Muscle mass assessed by the D3-creatine dilution method and incident self-reported disability and mortality in a prospective observational study of community-dwelling older men. J Gerontol Ser A Biol Sci Med Sci. 2020;76:123-30. doi:10.1093/GERONA/GLAA111.Cawthon PM, Blackwell T, Cummings SR, et al. Muscle mass assessed by the D3-creatine dilution method and incident self-reported disability and mortality in a prospective observational study of community-dwelling older men. J Gerontol Ser A Biol Sci Med Sci. 2020;76:123-30. doi:10.1093/GERONA/GLAA111.Mancinelli R, Checcaglini F, Coscia F, et al. Biological aspects of selected myokines in skeletal muscle: focus on aging. Int J Mol Sci. 2021;22:8520. doi:10.3390/ijms22168520.Mancinelli R, Checcaglini F, Coscia F, et al. Biological aspects of selected myokines in skeletal muscle: focus on aging. Int J Mol Sci. 2021;22:8520. doi:10.3390/ijms22168520.Paris MT, Bell KE, Mourtzakis M.Myokines and adipokines in sarcopenia: understanding cross-talk between skeletal muscle and adipose tissue and the role of exercise. Curr Opin Pharmacol. 2020;52:61-6. doi:10.1016/j.coph.2020.06.003.l.Paris MT, Bell KE, Mourtzakis M.Myokines and adipokines in sarcopenia: understanding cross-talk between skeletal muscle and adipose tissue and the role of exercise. Curr Opin Pharmacol. 2020;52:61-6. doi:10.1016/j.coph.2020.06.003.l.Bilski J, Pierzchalski P, Szczepanik M, et al. Multifactorial Mechanism of Sarcopenia and Sarcopenic Obesity. Role of Physical Exercise, Microbiota and Myokines. Cells. 2022;11(1):160. doi:10.3390/cells11010160.Bilski J, Pierzchalski P, Szczepanik M, et al. Multifactorial Mechanism of Sarcopenia and Sarcopenic Obesity. Role of Physical Exercise, Microbiota and Myokines. Cells. 2022;11(1):160. doi:10.3390/cells11010160.Eilers W, Chambers D, Cleasby M, Foster K.Local myostatin inhibition improves skeletal muscle glucose uptake in insulin-resistant high-fat diet-fed mice. Am. J. Physiol. Endocrinol. Metab. 2020;319:E163-E174. doi:10.1152/ajpendo.00185.2019.Eilers W, Chambers D, Cleasby M, Foster K.Local myostatin inhibition improves skeletal muscle glucose uptake in insulin-resistant high-fat diet-fed mice. Am. J. Physiol. Endocrinol. Metab. 2020;319:E163-E174. doi:10.1152/ajpendo.00185.2019.Willis SA, Sargeant JA, Thackray AE, et al. Effect of exercise intensity on circulating hepatokine concentrations in healthy men. Appl. Physiol. Nutr. Metab. 2019;44:1065-72. doi:10.1139/apnm-2018-0818.Willis SA, Sargeant JA, Thackray AE, et al. Effect of exercise intensity on circulating hepatokine concentrations in healthy men. Appl. Physiol. Nutr. Metab. 2019;44:1065-72. doi:10.1139/apnm-2018-0818.Hjorth M, Pourteymour S, Gorgens SW, et al. Myostatin in relation to physical activity and dysglycaemia and its effect on energy metabolism in human skeletal muscle cells. Acta Physiol. 2016;217:45-60. doi:10.1111/apha.12631.Hjorth M, Pourteymour S, Gorgens SW, et al. Myostatin in relation to physical activity and dysglycaemia and its effect on energy metabolism in human skeletal muscle cells. Acta Physiol. 2016;217:45-60. doi:10.1111/apha.12631.Consitt LA, Clark BC. The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials. J.Frailty Aging. 2018;7:21-7. doi:10.14283/jfa.2017.33.Consitt LA, Clark BC. The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials. J.Frailty Aging. 2018;7:21-7. doi:10.14283/jfa.2017.33.Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12:2401. doi:10.3390/nu12082401.Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12:2401. doi:10.3390/nu12082401.Bergen HR, Farr JN, Vanderboom PM, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle. 2015;5:21. doi:10.1186/s13395-015-0047-5.Bergen HR, Farr JN, Vanderboom PM, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle. 2015;5:21. doi:10.1186/s13395-015-0047-5.Schafer MJ, Atkinson EJ, Vanderboom PM, et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab. 2016;23:1207-15. doi:10.1016/j.cmet.2016.05.023.Schafer MJ, Atkinson EJ, Vanderboom PM, et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab. 2016;23:1207-15. doi:10.1016/j.cmet.2016.05.023.Tam Dao, Green AE, Kim YA, et al. Sarcopenia and Muscle Aging: A Brief Overview. Endocrinol Metab (Seoul). 2020;35(4):716-32. doi:10.3803/EnM.2020.4053.Tam Dao, Green AE, Kim YA, et al. Sarcopenia and Muscle Aging: A Brief Overview. Endocrinol Metab (Seoul). 2020;35(4):716-32. doi:10.3803/EnM.2020.4053.Fife E, Kostka J, Kroc Ł, et al. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr. 2018;18:200. doi:10.1186/s12877-018-0888-y.Fife E, Kostka J, Kroc Ł, et al. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr. 2018;18:200. doi:10.1186/s12877-018-0888-y.Ladang A, Beaudart C, Reginster J-Y, et al. Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcif Tissue Int. 2023;112(2):197-217. doi:10.1007/s00223-022-01054-z.Ladang A, Beaudart C, Reginster J-Y, et al. Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcif Tissue Int. 2023;112(2):197-217. doi:10.1007/s00223-022-01054-z.Johann K, Kleinert M, Klaus S.The role of gdf15 as a myomitokine. Cells. 2021;10:2990. doi:10.3390/cells10112990.Johann K, Kleinert M, Klaus S.The role of gdf15 as a myomitokine. Cells. 2021;10:2990. doi:10.3390/cells10112990.Yamamoto H, Takeshima F, Haraguchi M, et al. High serum concentrations of growth differentiation factor-15 and their association with Crohn’s disease and a low skeletal muscle index. Sci Rep. 2022;12:6591. doi:10.1038/s41598-022-10587-0.Yamamoto H, Takeshima F, Haraguchi M, et al. High serum concentrations of growth differentiation factor-15 and their association with Crohn’s disease and a low skeletal muscle index. Sci Rep. 2022;12:6591. doi:10.1038/s41598-022-10587-0.Seo MW, Jung SW, Kim SW, et al. Effects of 16 weeks of resistance training on muscle quality and muscle growth factors in older adult women with sarcopenia: a randomized controlled trial. Int J Environ Res Public Health. 2021;18:6762. doi:10.3390/ijerph18136762.Seo MW, Jung SW, Kim SW, et al. Effects of 16 weeks of resistance training on muscle quality and muscle growth factors in older adult women with sarcopenia: a randomized controlled trial. Int J Environ Res Public Health. 2021;18:6762. doi:10.3390/ijerph18136762.Rodriguez A, Becerril S, Ezquerro S, et al. Crosstalk between adipokines and myokines in fat browning. Acta Physiol. 2017;219:362-81. doi:10.1111/apha.12686.Rodriguez A, Becerril S, Ezquerro S, et al. Crosstalk between adipokines and myokines in fat browning. Acta Physiol. 2017;219:362-81. doi:10.1111/apha.12686.Park HS, Kim HC, Zhang D, et al. The novel myokine irisin: Clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. Endocrine. 2019;64:341-8. doi:10.1007/s12020-018-1814-y.Park HS, Kim HC, Zhang D, et al. The novel myokine irisin: Clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. Endocrine. 2019;64:341-8. doi:10.1007/s12020-018-1814-y.Calvani R, Marini F, Cesari M, et al. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle. 2015;6(4):278-86. doi:10.1002/jcsm.12051.Calvani R, Marini F, Cesari M, et al. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle. 2015;6(4):278-86. doi:10.1002/jcsm.12051.Hettwer S, Dahinden P, Kucsera S, et al. Elevated levels of a C‐terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol. 2013;48:69-75. doi:10.1016/j.exger.2012.03.002.Hettwer S, Dahinden P, Kucsera S, et al. Elevated levels of a C‐terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol. 2013;48:69-75. doi:10.1016/j.exger.2012.03.002.Yu D, Li HX, Liu Y, et al. The reference intervals for serum C‐terminal agrin fragment in healthy individuals and as a biomarker for renal function in kidney transplant recipients. J Clin Lab Anal. 2017;31:e22059. doi:10.1002/jcla.22059.Yu D, Li HX, Liu Y, et al. The reference intervals for serum C‐terminal agrin fragment in healthy individuals and as a biomarker for renal function in kidney transplant recipients. J Clin Lab Anal. 2017;31:e22059. doi:10.1002/jcla.22059.Guo A, Li K, Xiao Q.Sarcopenic obesity: Myokines as potential diagnostic biomarkers and therapeutic targets? Exp. Gerontol. 2020;139:111022. doi:10.1016/j.exger.2020.111022.Guo A, Li K, Xiao Q.Sarcopenic obesity: Myokines as potential diagnostic biomarkers and therapeutic targets? Exp. Gerontol. 2020;139:111022. doi:10.1016/j.exger.2020.111022.Gonzalez Rodriguez E, Marques-Vidal P, Aubry-Rozier B, et al. Diurnal salivary cortisol in sarcopenic postmenopausal women: the OsteoLaus cohort. Calcif Tissue Int. 2021;109:499-509. doi:10.1007/s00223-021-00863-y.Gonzalez Rodriguez E, Marques-Vidal P, Aubry-Rozier B, et al. Diurnal salivary cortisol in sarcopenic postmenopausal women: the OsteoLaus cohort. Calcif Tissue Int. 2021;109:499-509. doi:10.1007/s00223-021-00863-y.Curcio F, Ferro G, Basile C, et al. Biomarkers in sarcopenia: a multifactorial approach. Exp Gerontol. 2016;85:1-8. doi:10.1016/j.exger.2016.09.007.Curcio F, Ferro G, Basile C, et al. Biomarkers in sarcopenia: a multifactorial approach. Exp Gerontol. 2016;85:1-8. doi:10.1016/j.exger.2016.09.007.Mancuso P, Bouchard B.The impact of aging on adipose function and adipokine synthesis. Front Endocrinol. 2019;10:137. doi:10.3389/fendo.2019.00137.Mancuso P, Bouchard B.The impact of aging on adipose function and adipokine synthesis. Front Endocrinol. 2019;10:137. doi:10.3389/fendo.2019.00137.Rost S, Freuer D, Peters A, et al. New indexes of body fat distribution and sex-specific risk of total and cause-specific mortality: A prospective cohort study. BMC Public Health. 2018;18(1):427. doi:10.1186/s12889-018-5350-8.Rost S, Freuer D, Peters A, et al. New indexes of body fat distribution and sex-specific risk of total and cause-specific mortality: A prospective cohort study. BMC Public Health. 2018;18(1):427. doi:10.1186/s12889-018-5350-8.Hajri T, Tao H, Wattacheril J, et al. Regulation of adiponectin production by insulin: Interactions with tumor necrosis factor-α and interleukin-6. Am J Physiol - Endocrinol Metab. 2011;300:239-42. doi:10.1152/ajpendo.00307.2010.Hajri T, Tao H, Wattacheril J, et al. Regulation of adiponectin production by insulin: Interactions with tumor necrosis factor-α and interleukin-6. Am J Physiol - Endocrinol Metab. 2011;300:239-42. doi:10.1152/ajpendo.00307.2010.Komici K, Dello Iacono A, De Luca A, et al. Adiponectin and Sarcopenia: a systematic review with meta-analysis. Front Endocrinol. 2021;12:329. doi:10.3389/fendo.2021.576619.Komici K, Dello Iacono A, De Luca A, et al. Adiponectin and Sarcopenia: a systematic review with meta-analysis. Front Endocrinol. 2021;12:329. doi:10.3389/fendo.2021.576619.Ahmad SS, Ahmad K, Lee EJ, et al. Implications of Insulin-Like Growth Factor-1 in Skeletal Muscle and Various Diseases. Cells. 2020;9:1773. doi:10.3390/cells9081773.Ahmad SS, Ahmad K, Lee EJ, et al. Implications of Insulin-Like Growth Factor-1 in Skeletal Muscle and Various Diseases. Cells. 2020;9:1773. doi:10.3390/cells9081773.Naranjo JD, Dziki JL, Badylak SF. Regenerative Medicine Approaches for Age-Related Muscle Loss and Sarcopenia: A Mini-Review. Gerontology. 2017;63:580-9. doi:10.1159/000479278.Naranjo JD, Dziki JL, Badylak SF. Regenerative Medicine Approaches for Age-Related Muscle Loss and Sarcopenia: A Mini-Review. Gerontology. 2017;63:580-9. doi:10.1159/000479278.Poggiogalle E, Lubrano C, Gnessi L, et al. Fatty Liver Index Associates with Relative Sarcopenia and GH/IGF-1 Status in Obese Subjects. PLoS ONE. 2016;11:e0145811. doi:10.1371/journal.pone.0145811.Poggiogalle E, Lubrano C, Gnessi L, et al. Fatty Liver Index Associates with Relative Sarcopenia and GH/IGF-1 Status in Obese Subjects. PLoS ONE. 2016;11:e0145811. doi:10.1371/journal.pone.0145811.Nie YZ, Yan ZQ, Yin H, et al. Osteosarcopenic obesity and its components — osteoporosis, sarcopenia, and obesity — are associated with blood cell count-derived inflammation indices in older Chinese people. BMC Geriatr. 2022;22:532. doi:10.1186/s12877-022-03225-x.Nie YZ, Yan ZQ, Yin H, et al. Osteosarcopenic obesity and its components — osteoporosis, sarcopenia, and obesity — are associated with blood cell count-derived inflammation indices in older Chinese people. BMC Geriatr. 2022;22:532. doi:10.1186/s12877-022-03225-x.

The authors declare that there are no conflicts of interest present.